金斯瑞生物科技(01548)：传奇生物三季度合作收入为1.428亿美元，同比增长88.14%

智通财经11-13

智通财经APP讯，金斯瑞生物科技(01548)公布传奇生物2024年第三季度业绩， CARVYKTI (西达基奥仑赛;cilta-cel)净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长 53.2%。合作收入为1.428亿美元，同比增长88.14%，增长主要是由于与杨森协议有关的CARVYKTI®销售收入增加。净亏损为1.253亿美元，2023年同期为6220万美元。截至2024...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483129066?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-13 06:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483129066","market":"hk","top_or_hot":-1,"title":"金斯瑞生物科技(01548)：传奇生物三季度合作收入为1.428亿美元，同比增长88.14%","media":"智通财经","content":"<div>\n<p>智通财经APP讯，金斯瑞生物科技(01548)公布传奇生物2024年第三季度业绩， CARVYKTI (西达基奥仑赛;cilta-cel)净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长 53.2%。 合作收入为1.428亿美元，同比增长88.14%，增长主要是由于与杨森协议有关的CARVYKTI®销售收入增加。净亏损为1.253亿美元，2023年同期为6220万美元。截至2024...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1210143.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>金斯瑞生物科技(01548)：传奇生物三季度合作收入为1.428亿美元，同比增长88.14%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n金斯瑞生物科技(01548)：传奇生物三季度合作收入为1.428亿美元，同比增长88.14%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 06:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1210143.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，金斯瑞生物科技(01548)公布传奇生物2024年第三季度业绩， CARVYKTI (西达基奥仑赛;cilta-cel)净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长 53.2%。 合作收入为1.428亿美元，同比增长88.14%，增长主要是由于与杨森协议有关的CARVYKTI®销售收入增加。净亏损为1.253亿美元，2023年同期为6220万美元。截至2024...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1210143.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1210143.html","article_id":"2483129066","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483129066","pubTimestamp":1731450019,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，金斯瑞生物科技 公布传奇生物2024年第三季度业绩， CARVYKTI 净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长 53.2%。合作收入为1.428亿美元，同比增长88.14%，增长主要是由于与杨森协议有关的CARVYKTI销售收入增加。净亏损为1.253亿美元，2023年同期为6220万美元。截至2024年9月30日，现金及现金等价物和定期存款达到12亿美元，传奇生物认为这些资金将提供直至2026年的财务储备，传奇生物预计在 2026年实现经营利润。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK1141":"生命科学工具和服务","BK4139":"生物科技","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","01548":"金斯瑞生物科技","BK1576":"医药外包概念","BK4588":"碎股","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK1583":"高瓴概念","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","LEGN":"传奇生物"},"translate_title":"GenScript Biotechnology (01548): Legend Biotech's cooperation revenue in the third quarter was US $142.8 million, a year-on-year increase of 88.14%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1,"LEGN":1},"content_text":"智通财经APP讯，金斯瑞生物科技(01548)公布传奇生物2024年第三季度业绩， CARVYKTI (西达基奥仑赛;cilta-cel)净贸易销售额约为2.86亿美元，营收同比增长87.6%，环比增长 53.2%。 合作收入为1.428亿美元，同比增长88.14%，增长主要是由于与杨森协议有关的CARVYKTI®销售收入增加。净亏损为1.253亿美元，2023年同期为6220万美元。截至2024年9月30日，现金及现金等价物和定期存款达到12亿美元，传奇生物认为这些资金将提供直至2026年的财务储备，传奇生物预计在 2026年实现经营利润。传奇生物首席执行官黄颖博士表示：“ 我们对第三季度取得了销售的强劲增长感到满意。在此期间，我们持续提升商业化能力并将CARVYKTI 带给全球更多的多发性骨髓瘤患者。来自CARTITUDE-4研究的积极数据进一步巩固了我们的竞争地位。与早至二线治疗的标准疗法相比， CARVYKTI 是目前首个且唯一能显著延长多发性骨髓瘤患者总生存期的细胞疗法。这凸显了此款疗法的变革性获益以及我们努力扩大患者可及性物在细胞治疗创新领域的领导地位。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483129066"}